Results 171 to 180 of about 49,037 (222)
Postepy biochemii, 1973 Some of the next articles are maybe not open access.
Related searches:
Related searches:
American Journal of Health-System Pharmacy, 1972
Rifampin is a potent antituberculous drug. In the treatment of drug-resistant tuberculosis it is highly effective provided it is given in combination with other drugs to which the patient's organisms are sensitive. Rifampin and ethambutol is a particularly powerful combination and will achieve almost 100% sputum conversion.
M, Schonell, E, Dorken, S, Grzybowski
openaire +4 more sources
Rifampin is a potent antituberculous drug. In the treatment of drug-resistant tuberculosis it is highly effective provided it is given in combination with other drugs to which the patient's organisms are sensitive. Rifampin and ethambutol is a particularly powerful combination and will achieve almost 100% sputum conversion.
M, Schonell, E, Dorken, S, Grzybowski
openaire +4 more sources
Annals of internal medicine, 1976
In 1971, rifampin was approved for treatment of pulmonary tuberculosis and asymptomatic carriers of Neisseria meningitidis. At present, the approved indications remain the same. However, rifampin in conjunction with at least one other antituberculous drug may be of great value in therapy of extrapulmonary tuberculosis and infections due to other ...
Gian G. Gallo, Pietro Radaelli
openaire +3 more sources
In 1971, rifampin was approved for treatment of pulmonary tuberculosis and asymptomatic carriers of Neisseria meningitidis. At present, the approved indications remain the same. However, rifampin in conjunction with at least one other antituberculous drug may be of great value in therapy of extrapulmonary tuberculosis and infections due to other ...
Gian G. Gallo, Pietro Radaelli
openaire +3 more sources
International Journal of Dermatology, 1993
Rifampicin (Rp) is a semisynthetic derivative of Rifamycin B, an antimicrobial agent produced by Streptomyces mediterranei. Rp is a broad spectrum antimicrobial and inhibits the growth of most Gram-positive bacteria, as well as many Gram-negative microorganisms, such as Escherichia coli, Pseudomonas, indole-positive and indole-negative Proteus, and ...
N K, Tsankov, J A, Kamarashev
openaire +2 more sources
Rifampicin (Rp) is a semisynthetic derivative of Rifamycin B, an antimicrobial agent produced by Streptomyces mediterranei. Rp is a broad spectrum antimicrobial and inhibits the growth of most Gram-positive bacteria, as well as many Gram-negative microorganisms, such as Escherichia coli, Pseudomonas, indole-positive and indole-negative Proteus, and ...
N K, Tsankov, J A, Kamarashev
openaire +2 more sources
Pediatrics In Review, 1996
Rifampin is a semisynthetic derivative of rifamycin B that is active against a wide range of microorganisms and bactericidal for extracellular as well as intracellular pathogens. Most gram-positive and many gram-negative bacteria, as well as mycobactenia, are inhibited by nifampin.
openaire +2 more sources
Rifampin is a semisynthetic derivative of rifamycin B that is active against a wide range of microorganisms and bactericidal for extracellular as well as intracellular pathogens. Most gram-positive and many gram-negative bacteria, as well as mycobactenia, are inhibited by nifampin.
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1972
To the Editor.— Rifampin is an effective antituberculous drug recently approved by the Food and Drug Administration for general use. Users are warned that Rifampin has been shown to produce liver dysfunction. There have been fatalities associated with jaundice in patients with liver disease or receiving rifampin concomitantly with other hepatotoxic ...
openaire +2 more sources
To the Editor.— Rifampin is an effective antituberculous drug recently approved by the Food and Drug Administration for general use. Users are warned that Rifampin has been shown to produce liver dysfunction. There have been fatalities associated with jaundice in patients with liver disease or receiving rifampin concomitantly with other hepatotoxic ...
openaire +2 more sources
TO RIFAMPIN OR NOT TO RIFAMPIN?!
Journal of the American College of Cardiology, 2022Faysal Alhasan +2 more
openaire +1 more source
Interaction of Rifampin and Chlorpropamide
Chest, 1980A 62-year-old man who had been taking 250 mg of chlorpropamide daily for several years received rifampin concomitantly and had a subsequent increased dosing requirement of chlorpropamide. When rifampin was discontinued several months later, the serum chlorpropamide concentration rose dramatically.
T H, Self, T, Morris
openaire +2 more sources